Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T03313
|
||||
Former ID |
TTDR01101
|
||||
Target Name |
Interleukin-2 receptor alpha chain
|
||||
Gene Name |
IL2RA
|
||||
Synonyms |
CD25 antigen; IL-2 receptor alpha subunit; P55; TAC antigen; IL2RA
|
||||
Target Type |
Successful
|
||||
Disease | Autoimmune diabetes [ICD10: E08-E13] | ||||
Chronic lymphocytic leukaemia [ICD10: C91] | |||||
Human immunodeficiency virus infection [ICD9: 279.3; ICD10: B20-B26] | |||||
Heart transplant rejection [ICD9: 996; ICD10: T86] | |||||
Hodgkin's lymphoma [ICD10: C81] | |||||
Organ transplant rejection [ICD9: 279.5, 996; ICD10: D89.8, T86] | |||||
Function |
Receptor for interleukin-2.
|
||||
BioChemical Class |
Transmembrane protein
|
||||
Target Validation |
T03313
|
||||
UniProt ID | |||||
Sequence |
MDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKS
GSLYMLCTGNSSHSSWDNQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQAS LPGHCREPPPWENEATERIYHFVVGQMVYYQCVQGYRALHRGPAESVCKMTHGKTRWTQP QLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATMETSIFTTEYQ VAVAGCVFLLISVLLLSGLTWQRRQRKSRRTI |
||||
Drugs and Mode of Action | |||||
Drug(s) | Basiliximab | Drug Info | Approved | Organ transplant rejection | [1], [2] |
Inolimomab | Drug Info | Phase 3 | Heart transplant rejection | [3] | |
LMB-2 | Drug Info | Phase 2 | Chronic lymphocytic leukaemia | [4] | |
RFT-5.dgA | Drug Info | Phase 2 | Human immunodeficiency virus infection | [5] | |
CHT-25 | Drug Info | Phase 1 | Hodgkin's lymphoma | [6] | |
HuMax-TAC | Drug Info | Terminated | Autoimmune diabetes | [7] | |
Modulator | Basiliximab | Drug Info | [8] | ||
CHT-25 | Drug Info | [6] | |||
Inolimomab | Drug Info | ||||
LMB-2 | Drug Info | [4] | |||
RFT-5.dgA | Drug Info | ||||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
Endocytosis | |||||
PI3K-Akt signaling pathway | |||||
Jak-STAT signaling pathway | |||||
Hematopoietic cell lineage | |||||
Measles | |||||
HTLV-I infection | |||||
NetPath Pathway | IL5 Signaling Pathway | ||||
TCR Signaling Pathway | |||||
IL2 Signaling Pathway | |||||
TNFalpha Signaling Pathway | |||||
Leptin Signaling Pathway | |||||
PANTHER Pathway | Interleukin signaling pathway | ||||
Pathway Interaction Database | IL12-mediated signaling events | ||||
Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||||
Arf6 trafficking events | |||||
SHP2 signaling | |||||
IL2-mediated signaling events | |||||
IL2 signaling events mediated by PI3K | |||||
IL2 signaling events mediated by STAT5 | |||||
Calcium signaling in the CD4+ TCR pathway | |||||
Downstream signaling in na& | |||||
#xef | |||||
ve CD8+ T cells | |||||
IL12 signaling mediated by STAT4 | |||||
Reactome | GPVI-mediated activation cascade | ||||
gamma signalling through PI3Kgamma | |||||
Interleukin-2 signaling | |||||
RAF/MAP kinase cascade | |||||
Interleukin receptor SHC signaling | |||||
WikiPathways | IL-2 Signaling Pathway | ||||
Inflammatory Response Pathway | |||||
Interleukin-2 signaling | |||||
Allograft Rejection | |||||
TSLP Signaling Pathway | |||||
IL-7 Signaling Pathway | |||||
Interleukin-3, 5 and GM-CSF signaling | |||||
References | |||||
REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6879). | ||||
REF 3 | New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. | ||||
REF 4 | Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000 Apr;18(8):1622-36. | ||||
REF 5 | ClinicalTrials.gov (NCT00667017) RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma. U.S. National Institutes of Health. | ||||
REF 6 | A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma. Clin Cancer Res. 2009 Dec 15;15(24):7701-7710. | ||||
REF 7 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018175) | ||||
REF 8 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.